The role of carnitine in the regulation of energy metabolism and modulation of the course of cardiovascular diseases and diabetes mellitus

Authors

  • O.O. Khaniukov State Institution “Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine”, Dnipro, Ukraine
  • O.V. Smolianova State Institution “Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine”, Dnipro, Ukraine

DOI:

https://doi.org/10.22141/2224-1485.13.2-3.2020.205334

Keywords:

carnitine, regulation of energy exchange, regulation of metabolism, cardiovascular diseases, β-oxidation of fatty acids, glycolysis, myocardial ischemia, acute myocardial infarction, chronic ischemic heart disease, heart rhythm disorders, chronic heart failure, atherosclerotic lesions of the lower

Abstract

Despite significant advances in prevention and treatment, cardiovascular diseases (CVD) continue to be a leader in terms of the prevalence and mortality among all diseases not only in Ukraine but also in most countries of the world. Given that comorbidity is inherent in CVD patients, it is very important to prescribe drugs whose mechanisms of action would be directed to the common links of pathogenesis of the most typical coexisting diseases in order to avoid polypharmacy. Such links are ischemia, impaired glucose and lipid metabolism. In addition, it should be noted that the last paradigm of the pharmacological industry is on the one hand the development of new drugs, and on the other hand — the introduction into clinical practice of existing drugs the effect of which would be directed at different links of CVD pathogenesis. The purpose of this review was to substantiate the possibility of prescribing carnitine to patients with CVD and diabetes mellitus from the perspective of its biochemical and pathogenetic effects on the course of these diseases, as well as the available experimental data and results of clinical studies evaluating the effectiveness and safety of carnitine. In the first part of the review, considerable attention was paid to the available literature data on energy metabolism in the cardiac and skeletal muscles, as well as the experimentally proven role of carnitine in physiological conditions and in the presence of ischemia. The second part of the publication deals with the review of clinical studies on the effect of carnitine administration on the course of coronary heart disease with acute and chronic course, intermittent lameness, impaired glucose tolerance, dyslipidemia. The analyzed literature allows us to make a reasonable conclusion that carnitine has antianginal, anti-ischemic, antihypoxic, antioxidant and membrane-stabilizing effects, which enables to influence positively the clinical course of CVD. Therefore, given the numerous mechanisms of action of carnitine, its use in the comprehensive treatment of patients with various pathologies is consistent with the newest paradigm of the pharmacological industry.

Downloads

Download data is not yet available.

References

Стан здоров’я народу України та медичної допомоги третинного рівня. Рекомендації для кардіологів, ревматологів, терапевтів, організаторів охорони здоров’я та лікарів загальної практики / за ред. В.М. Коваленко, В.М. Корнацького. Київ: ДУ «ННЦ «Інститут кардіології імені академіка М.Д. Стражеска», 2019. 224 c.

Zimmermann G.R., Lehár J., Keith C.T. Multi-target the-rapeutics: when the whole is greater than the sum of the parts. Drug Discovery Today. 2007. Vol. 12. № 1–2. Р. 34-42.

Ferrari R., Camici P.G., Crea F. et al. Expert consensus document: A “diamond” approach to personalized treatment of angina. Nature Reviews. Cardiology. 2018. Vol. 15. № 2. Р. 120-132.

Calvani M., Reda E., Arrigoni-Martelli E. Regulation by carnitine of myocardial fatty acid and carbohydrate metabolism under normal and pathological conditions. Basic Research in Cardiology. 2000. Vol. 95. № 2. Р. 75-83.

Doenst T., Nguyen T.D., Abel E.D. Cardiac metabolism in heart failure: implications beyond ATP production. Circulation Research. 2013. Vol. 113. № 6. Р. 709-724.

Pascual F., Coleman R.A. Fuel availability and fate in cardiac metabolism: A tale of two substrates. Biochimica еt Biophysica Acta. 2016. Vol. 1861. № 10. Р. 1425-1433.

Lango R. Influence of L-carnitine and its derivatives on myocardial metabolism and function in ischemic heart disease and during cardiopulmonary bypass. Cardiovascular Research. 2001. Vol. 51. № 1. Р. 21-29.

Carvajal K., Moreno-Sánchez R. Heart metabolic disturbances in cardiovascular diseases. Archives of Medical Research. 2003. Vol. 34. № 2. Р. 89-99.

Paulson D.J. Carnitine deficiency-induced cardiomyopathy. Molecular and Cellular Biochemistry. 1998. Vol. 180. № 1/2. Р. 33-41.

Vusse G.J. van der, Glatz J.F., Stam H.C. et al. Fatty acid homeostasis in the normoxic and ischemic heart. Physiological Reviews. 1992. Vol. 72. № 4. Р. 881-940.

Lopaschuk G.D., Ussher J.R., Folmes C.D.L. et al. Myocardial fatty acid metabolism in health and disease. Physiological Reviews. 2010. Vol. 90. № 1. Р. 207-258.

Stanley W. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions Potential for pharmacological interventions. Cardiovascular Research. 1997. Vol. 33. № 2. Р. 243-257.

Ronner P. Netter’s Essential Biochemistry: Elsevier, 2018. 496 c.

Dinicolantonio J.J., Niazi A.K., McCarty M.F. et al. L-carnitine for the treatment of acute myocardial infarction. Reviews in Cardiovascular Medicine. 2014. Vol. 15. № 1. Р. 52-62.

Zammit V.A., Ramsay R.R., Bonomini M. et al. Carnitine, mitochondrial function and therapy. Advanced Drug Delivery Reviews. 2009. Vol. 61. № 14. Р. 1353-1362.

D’Antona G., Nabavi S.M., Micheletti P. et al. Creatine, L-Carnitine, and ω 3 Polyunsaturated Fatty Acid Supplementation from Healthy to Diseased Skeletal Muscle. BioMed Research International. 2014. Vol. 2014. C. 1-16.

Steiber A., Kerner J., Hoppel C.L. Carnitine: a nutritio-nal, biosynthetic, and functional perspective. Molecular Aspects of Medicine. 2004. Vol. 25. № 5–6. Р. 455-473.

Mingorance C., Rodríguez-Rodríguez R., Justo M.L. et al. Critical update for the clinical use of L-carnitine analogs in cardiometabolic disorders. Vascular Health and Risk Management. 2011. Vol. 7. Р. 169-176.

Mynatt R.L. Carnitine and type 2 diabetes. Diabetes/metabolism research and reviews. 2009. Vol. 25. Suppl. 1. Р. S45-S49.

Broderick T.L., Quinney H.A., Lopaschuk G.D. Carnitine stimulation of glucose oxidation in the fatty acid perfused isolated working rat heart. The Journal of Biological Chemistry. 1992. Vol. 267. № 6. Р. 3758-3763.

Ferdinandy P., Schulz R., Baxter G.F. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacological Reviews. 2007. Vol. 59. № 4. C. 418-458.

Asadi M., Rahimlou M., Shishehbor F. et al. The effect of l-carnitine supplementation on lipid profile and glycaemic control in adults with cardiovascular risk factors: A systematic review and meta-analysis of randomized controlled clinical trials. Clinical Nutrition (Edinburgh, Scotland). 2020. Vol. 3. № 1. Р. 110-122.

Abdel-aleem S., Nada M.A., Sayed-Ahmed M. et al. Regulation of fatty acid oxidation by acetyl-CoA generated from glucose utilization in isolated myocytes. Journal of Molecular and Cellular Cardiology. 1996. Vol. 28. № 5. Р. 825-833.

Fritz I.B., Arrigoni-Martelli E. Sites of action of carnitine and its derivatives on the cardiovascular system: interactions with membranes. Trends in Pharmacological Sciences. 1993. Vol. 14. № 10. Р. 355-360.

Oliver M.F. Prevention of ventricular fibrillation during acute myocardial ischemia: control of free fatty acids. Journal of Cardiovascular Pharmacology and Therapeutics. 2001. Vol. 6. № 3. Р. 213-217.

Ferrari R., Merli E., Cicchitelli G. et al. Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review. Annals of the New York Academy of Sciences. 2004. Vol. 1033. Р. 79-91.

Singh R.B., Niaz M.A., Agarwal P. et al. A randomised, double-blind, placebo-controlled trial of L-carnitine in suspected acute myocardial infarction. Postgraduate Medical Journal. 1996. Vol. 72. № 843. Р. 45-50.

DiNicolantonio J.J., Lavie C.J., Fares H. et al. L-carnitine in the secondary prevention of cardiovascular disease: syste-matic review and meta-analysis. Mayo Clinic Proceedings. 2013. Vol. 88. № 6. Р. 544-551.

Rizzon P., Biasco G., Di Biase M. et al. High doses of L-carnitine in acute myocardial infarction: metabolic and antiarrhythmic effects. European Heart Journal. 1989. Vol. 10. № 6. Р. 502-508.

Martina B., Zuber M., Weiss P. et al. Anti-arrhythmia treatment using L-carnitine in acute myocardial infarct. Schwei-zerische Medizinische Wochenschrift. 1992. Vol. 122. № 37. Р. 1352-1355.

Tarantini G., Scrutinio D., Bruzzi P. et al. Metabolic treatment with L-carnitine in acute anterior ST segment elevation myocardial infarction. A randomized controlled trial. Cardiology. 2006. Vol. 106. № 4. Р. 215-223.

Jacoba K.G.C., Abarquez R.F., Topacio G.O. et al. Effect of L-Carnitine on the Limitation of Infarct Size in One-Month Postmyocardial Infarction Cases. Clinical Drug Investigation. 1996. Vol. 11. № 2. Р. 90-96.

Stanley W.C., Recchia F.A., Lopaschuk G.D. Myocardial Substrate Metabolism in the Normal and Failing Heart. Physiological Reviews. 2005. Vol. 85. № 3. Р. 1093-1129.

Iliceto S., Scrutinio D., Bruzzi P. et al. Effects of l-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the l-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) trial. Journal of the American College of Cardiology. 1995. Vol. 26. № 2. Р. 380-387.

Mardinoglu A., Ural D., Zeybel M. et al. The Potential Use of Metabolic Cofactors in Treatment of NAFLD. Nutrients. 2019. Vol. 11. № 7. Р. 1578.

Heggermont W.A., Papageorgiou A.-P., Heymans S. et al. Metabolic support for the heart: complementary therapy for heart failure? European Journal of Heart Failure. 2016. Vol. 18. № 12. Р. 1420-1429.

Omori Y., Ohtani T., Sakata Y. et al. L-Carnitine prevents the development of ventricular fibrosis and heart failure with preserved ejection fraction in hypertensive heart disease. Journal of Hypertension. 2012. Vol. 30. № 9. Р. 1834-1844.

Rattray N.J.W., Trivedi D.K., Xu Y. et al. Metabolic dysregulation in vitamin E and carnitine shuttle energy mechanisms associate with human frailty. Nature Communications. 2019. Vol. 10. № 1. Р. 1-12.

Vidal-Casariego A., Burgos-Peláez R., Martínez-Fae-do C. et al. Metabolic Effects of L-carnitine on Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis. Experimental and Clinical Endocrinology & Diabetes. 2013. Vol. 121. № 4. Р. 234-238.

Abolfathi M., Mohd-Yusof B.-N., Hanipah Z.N. et al. The effects of carnitine supplementation on clinical characte-ristics of patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials. Complementary Therapies in Medicine. 2020. Vol. 48. Р. 102273.

Fathizadeh H., Milajerdi A., Reiner Ž. et al. The Effects of L-Carnitine Supplementation on Serum Lipids: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Current Pharmaceutical Design. 2019. Vol. 25. № 30. Р. 3266-3281.

Xu Y., Jiang W., Chen G. et al. L-carnitine treatment of insulin resistance: A systematic review and meta-analysis. Advances in Clinical and Experimental Medicine: Official Organ Wroclaw Medical University. 2017. Vol. 26. № 2. Р. 333-338.

Mingrone G., Greco A.V., Capristo E. et al. L-carnitine improves glucose disposal in type 2 diabetic patients. Journal of the American College of Nutrition. 1999. Vol. 18. № 1. Р. 77-82.

Ringseis R., Keller J., Eder K. Role of carnitine in the regulation of glucose homeostasis and insulin sensitivity: evidence from in vivo and in vitro studies with carnitine supplementation and carnitine deficiency. European Journal of Nutrition. 2012. Vol. 51. № 1. Р. 1-18.

Li S., Chen X., Li Q. et al. Effects of acetyl-L-carnitine and methylcobalamin for diabetic peripheral neuropathy: A multicenter, randomized, double-blind, controlled trial. Journal of Diabetes Investigation. 2016. Vol. 7. № 5. Р. 777-785.

Li S., Li Q., Li Y. et al. Acetyl-L-carnitine in the treatment of peripheral neuropathic pain: a systematic review and meta-analysis of randomized controlled trials. PloS One. 2015. Vol. 10. № 3. Р. e0119479.

Rolim L.C., Silva E.M. da, Flumignan R.L. et al. Acetyl-L-carnitine for the treatment of diabetic peripheral neuropathy. Cochrane Database of Systematic Reviews. 2019.

Askarpour M., Hadi A., Symonds M.E. et al. Efficacy of l-carnitine supplementation for management of blood lipids: A systematic review and dose-response meta-analysis of randomized controlled trials. Nutrition, metabolism, and cardiovascular dise-ases: NMCD. 2019. Vol. 29. № 11. Р. 1151-1167.

Stephens F.B., Constantin-Teodosiu D., Laithwaite D. et al. An acute increase in skeletal muscle carnitine content alters fuel metabolism in resting human skeletal muscle. The Journal of Clinical Endocrinology & Metabolism. 2006. Vol. 91. № 12. Р. 5013-5018.

Hiatt W.R. Carnitine and peripheral arterial disease. Annals of the New York Academy of Sciences. 2004. Vol. 1033. Р. 92-98.

Wall B.T., Stephens F.B., Constantin-Teodosiu D. et al. Chronic oral ingestion of L-carnitine and carbohydrate increases muscle carnitine content and alters muscle fuel metabolism during exercise in humans. The Journal of Physiology. 2011. Vol. 589. P. 4. Р. 963-973.

Brevetti G., Perna S., Sabbá C. et al. Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. Journal of the American College of Cardiology. 1995. Vol. 26. № 6. Р. 1411-1416.

Brevetti G., Diehm C., Lambert D. European multicenter study on propionyl-L-carnitine in intermittent claudication. Journal of the American College of Cardiology. 1999. Vol. 34. № 5. Р. 1618-1624.

Luo T., Li J., Li L. et al. A study on the efficacy and safety assessment of propionyl-L-carnitine tablets in treatment of intermittent claudication. Thrombosis Research. 2013. Vol. 132. № 4. Р. 427-432.

Published

2021-09-25

How to Cite

Khaniukov, O., & Smolianova, O. (2021). The role of carnitine in the regulation of energy metabolism and modulation of the course of cardiovascular diseases and diabetes mellitus. HYPERTENSION, 13(2-3), 11–20. https://doi.org/10.22141/2224-1485.13.2-3.2020.205334

Issue

Section

Review